Stock Chart

ALT

$2.74 -0.91%
Score: 36.7 AVOID NEW MONEY
Pro
Screener
Vol: 1.12x (vs SPY: 1.1x | vs QQQ: 1.1x)
Volume Ratio Explained

Vol: Current volume vs 20-day average
vs SPY: Relative activity vs market
vs QQQ: Relative activity vs tech

Color Guide:
● Red (≥1.5x): High activity
● Yellow (≥1.2x): Above average
● Blue (≤0.7x): Low activity

Interpretation:
• vs SPY > 1: Stock-specific interest
• vs SPY < 1: Stock quiet vs market
Chart Pattern · as of Oct 02, 2026
No qualifying chart pattern in the trailing 60 sessions — we only flag setups that pass our quality gate.
Technical Chart
CHART OVERLAYS
Active: 2
INDICATORS
TRENDLINES
OPTIONS FLOW
VOLUME & PRICE
OTHER

About ALT - Altimmune, Inc. Common Stock

Altimmune Inc is a clinical-stage biopharmaceutical company focused on developing treatments for obesity, metabolic diseases, and liver diseases. Its product candidate, pemvidutide (formerly known as ALT-801), is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist. Pemvidutide is currently in clinical development for obesity and metabolic-associated steatohepatitis (MASH). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.

Key Statistics

Market Cap $537M

This ALT stock chart provides comprehensive technical analysis including candlestick patterns, volume profile analysis, and options open interest data. Track ALT's price movements with trendlines, gamma walls, and key support/resistance levels.